Testing effectiveness (Phase 2)Ended earlyNCT01018563What this trial is testingAn Open Label Extension Study of the Efficacy of MORAb-003Who this might be right forEpithelial Ovarian Cancer Morphotek 3
Large-scale testing (Phase 3)Active Not RecruitingNCT01874353What this trial is testingOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyWho this might be right forPlatinum SensitiveBRCA MutatedRelapsed Ovarian Cancer+1 more AstraZeneca 327
Large-scale testing (Phase 3)Study completedNCT03353831What this trial is testingAtezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian CancerWho this might be right forRecurrent Ovarian Carcinoma AGO Research GmbH 574
Large-scale testing (Phase 3)Looking for participantsNCT04921527What this trial is testingChiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian CancerWho this might be right forOvarian CancerRelapsed or RefractoryChiauranib+1 more Chipscreen Biosciences, Ltd. 454
Testing effectiveness (Phase 2)Looking for participantsNCT07410494What this trial is testingBiomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid TumorsWho this might be right forCancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more Essen Biotech 85
Not applicableUnknownNCT01851746What this trial is testingDocetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian CancerWho this might be right forRecurrent Ovarian Cancer Wuhan University 200
Testing effectiveness (Phase 2)Study completedNCT02289950What this trial is testingAssess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian CancerWho this might be right forPlatinum-Sensitive Ovarian Cancer in First Relapse Eisai Inc. 332
Early research (Phase 1)Study completedNCT01478685What this trial is testingCC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid TumorsWho this might be right forUrinary Bladder NeoplasmsCarcinoma, Transitional CellOvarian Neoplasms+5 more Celgene 169
Early research (Phase 1)Study completedNCT02303912What this trial is testingSafety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian CancerWho this might be right forRecurrent Ovarian Cancer Imperial College Healthcare NHS Trust 25
Large-scale testing (Phase 3)UnknownNCT03278717What this trial is testingStudy Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer PatientsWho this might be right forOvarian Cancer University College, London 330
Not applicableNot Yet RecruitingNCT06838429What this trial is testingPARPi and Ovarian Cancer SurvivalWho this might be right forEpithelial Ovarian Cancer, Fallopian Tube or PeritoneumPARP Inhibitor Shanghai Gynecologic Oncology Group 6,000
Not applicableEnded earlyNCT00904514What this trial is testingStudy of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical TrialWho this might be right forCancer National Institutes of Health Clinical Center (CC) 241
Large-scale testing (Phase 3)Looking for participantsNCT06791460What this trial is testingPegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian CancerWho this might be right forOvarian Cancer Recurrent Obstetrics & Gynecology Hospital of Fudan University 296
Testing effectiveness (Phase 2)UnknownNCT05475184What this trial is testingEvaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP InhibitorWho this might be right forOvarian Cancer Onconic Therapeutics Inc. 58
Testing effectiveness (Phase 2)Study completedNCT01705158What this trial is testingMyocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the PlatinumWho this might be right forOvarian Cancer ARCAGY/ GINECO GROUP 87
Testing effectiveness (Phase 2)Study completedNCT02354586What this trial is testingNiraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensWho this might be right forOvarian NeoplasmsOvarian Cancer Tesaro, Inc. 463
Not applicableStudy completedNCT00003538What this trial is testingPrevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow TransplantationWho this might be right forCancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Large-scale testing (Phase 3)Ended earlyNCT00324324What this trial is testingMoxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantWho this might be right forBreast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more OHSU Knight Cancer Institute 240
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108What this trial is testingLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasWho this might be right forBone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more M.D. Anderson Cancer Center 30
Not applicableStudy completedNCT02298855What this trial is testingIndividualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer.Who this might be right forOvarian Cancer University College, London 113